The article's lead section may need to be rewritten. (April 2021) |
Mark Emberton OBE is a urologist and prostate cancer research specialist using novel imaging techniques and minimally invasive treatments to improve diagnosis and treatment of prostate cancer.
Mark Emberton | |
|---|---|
| Nationality | British |
| Occupation | Urologist |
| Known for | Prostate Cancer Research |
| Academic work | |
| Institutions | University College London University College London Hospital |
Emberton is Professor of Interventional oncology at University College London and Dean of its Faculty of Medical Sciences.[1] and is Honorary Consultant Urological Surgeon at University College Hospital.[2] He serves as Founding Pioneer of the charity Prostate Cancer UK.[3]
Emberton is author of over 450 peer-reviewed articles on prostate cancer and urology-related topics in scientific journals, including The New England Journal of Medicine, The Lancet and The BMJ. His work has been cited almost 30,000 times.[4]
Early life and education
editEmberton was born in Edinburgh. He was educated at St Boniface's Catholic College before graduating from St Mary's Hospital Medical School with a Bachelor of Medicine/Bachelor of Surgery in Clinical Medicine in 1985. During his time at St. Mary’s, he completed an Intercalated BSc in Psychology at Bedford College (1983). He gained a Doctor of Medicine Degree in 1997 following a period of research at the Clinical Effectiveness Unit at the Royal College of Surgeons of England, where he led the national Prostatectomy Audit.
He was awarded a sub-specialty Fellowship of the Royal Colleges of Surgeons (FRCS Urol.) in 1997.
Research and career
editEmberton is Professor of Interventional Oncology at University College London and was appointed Dean of its Faculty of Medical Sciences in 2015.[5] He is also a clinical consultant and surgeon at University College Hospital, London, where he diagnoses and treats patients with prostate cancer.[2]
Emberton has a track record in taking ideas through the various phases of evaluation with the result of these ideas becoming a part of routine practice. He did this with self-management of lower urinary tract symptoms,[6] with magnetic resonance imaging for men at risk of prostate cancer[7] and, most recently, with tissue preserving therapies for prostate cancer.[8]
He oversaw the trial of multi-parametric MRI scanning as a first-line investigation for prostate cancer. The approach was approved by The National Institute for Health and Care Excellence (NICE) in May 2019.[9]
Emberton is Chief Investigator in The Medical Research Centre (MRC) and Cancer Research UK funded ReIMAGINE Prostate Cancer study which is looking at the determinants and consequences of MRI abnormalities in men[10]
Emberton and his team of researchers are exploring the role of focal therapy in men with prostate cancer.[11] The technique minimises damage to surrounding that tends to occur with surgery or radiotherapy. He led the evaluation of vascular targeted photo-therapy though phase I to phase III.
Honours and awards
editEmberton was appointed Officer of the Order of the British Empire (OBE) in the 2021 Birthday Honours for services to research and prostate cancer.[14]
References
edit- ^ "UCL IRIS Institutional Research Information Service".
- ^ a b "Our Consultants". NHS UCLH.
- ^ "Prostate Cancer Research UK The Pioneers".
- ^ "Google Scholar".
- ^ "UCL News". 14 May 2015.
- ^ "Self-management intervention for men with lower urinary tract symptoms". UCL. 10 December 2014.
- ^ "MRI scans to be trialled as test for prostate cancer". The Guardian.
- ^ Emberton, Mark (2018). "Has tailored, tissue-selective tumour ablation in men with prostate cancer come of age?". BJU International. 121 (5): 676–677. doi:10.1111/bju.14088. PMID 29687953. S2CID 22611696.
- ^ "Prostate cancer: diagnosis and management". NICE.
- ^ "ReIMAGINE Prostate Cancer Screening". Cancer Research UK. 20 January 2020.
- ^ Marconi, L.; Stonier, T.; Tourinho-Barbosa, R.; Moore, C.; Ahmed, H. U.; Cathelineau, X.; Emberton, M.; Sanchez-Salas, R.; Cathcart, P. (2019). "Robot-assisted Radical Prostatectomy After Focal Therapy: Oncological, Functional Outcomes and Predictors of Recurrence". European Urology. 76 (1): 27–30. doi:10.1016/j.eururo.2019.03.007. hdl:10044/1/69039. PMID 30904357. S2CID 85497979.
- ^ Wise, J. (2019). "The BMJ Awards 2019: UK Research Paper of the Year". BMJ (Clinical Research Ed.). 365: l1866. doi:10.1136/bmj.l1866. PMID 31018915. S2CID 131774459.
- ^ "Medals & Awards". BAUS.
- ^ "No. 63377". The London Gazette (Supplement). 12 June 2021. p. B11.